A veteran team of Connecticut drug developers has raised $93 million for their startup, Rallybio, which is working to acquire and develop a portfolio of pharmaceutical technologies to treat severe and rare disorders.
Rallybio was co-founded by three executives who previously worked together at Alexion Pharmaceuticals.